PD-L1 Expression Predicts Response to PD-1/PD-L1 Inhibition

PD-L1 expression by tumor and tumor-infiltrating immune cells is associated with higher response rates to anti–PD-1/PD-L1 antibodies among solid tumors.
PD-L1 expression by tumor and tumor-infiltrating immune cells is associated with higher response rates to anti–PD-1/PD-L1 antibodies among solid tumors.

PD-L1 expression by tumor and tumor-infiltrating immune cells is associated with higher response rates to anti–PD-1/PD-L1 antibodies among solid tumors, according to a study published in Precision Oncology.1

The role of PD-L1 testing as a biomarker for response to anti–PD-1/PD-L1 antibody treatment is not yet well-defined. This meta-analysis evaluated the predictive role PD-L1 expression by pooling data from multiple trials across several solid malignancies.

The analysis included 6664 patients from 41 distinct phase 1 to 3 clinical trials that evaluated nivolumab, pembrolizumab, atezolizumab, durvalumab, or avelumab in advanced non–small-cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, melanoma, gastroesophageal cancer, Merkel cell cancer, head and neck cancer, and small-cell lung cancer.

PD-L1 positivity by immunohistochemistry (IHC) was significantly associated with favorable response among all tumor types (odds ratio [OR], 2.26; 95% CI, 1.85-2.75; P < .001), but particularly for NSCLC (OR, 2.51; 95% CI, 1.99-3.17; P < .001), compared with PD-L1 negativity.

The favorable response to PD-1/PD-L1 inhibition in NSCLC was present among different PD-L1 expression thresholds, including 1% (OR, 2.17; 95% CI, 1.03-4.57), 5% (OR, 2.80; 95% CI, 1.56-5.02), and 10% (OR, 2.84; 1.40-5.77).

PD-L1 positivity was associated with treatment response regardless of which IHC assay was used. The ORs ranged from 2.02 to 4.42 for the 28-8, SP142, 22C3, 73-10, and SP263 assays.

RELATED: Radiation Resistance Correlates With PD-L1 Expression in HNSCC

The authors stated that these findings suggest that “detection of PD-L1 expression in tumor cells and tumor-infiltrating immune cells using IHC is highly accessible and has significant potential as a biomarker predictive of response to PD-1/PD-L1 axis therapies across various tumor types.”

Reference

  1. Khunger M, Hernandez AV, Pasupuleti V, et al. Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis. Precis Oncol. 2017 May 18. doi: 10.1200/PO.16.00030 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters